Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study

El-Khalili, Nizar; Joyce, Mark; Atkinson, Sarah; Buynak, Robert; Datto, Catherine; Lindgren, Petter; Eriksson, Hans

doi:10.1017/s1461145710000015

Public

Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study

Published in The International Journal of Neuropsychopharmacology • Feb 23, 2010

Authors:

Nizar El-Khalili

Mark Joyce

Sarah Atkinson

Abstract

This study evaluated once-daily extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in patients with major depressive disorder (MDD) with inadequate response to ongoing antidepressant treatment. In this 8-wk (6-wk active treatment/2-wk post-treatment drug-discontinuation/follo...

Subject

Quetiapine

Quetiapine Fumarate

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!